

**Gap Analysis: Benzodiazepines**  
**The International Benzodiazepine Symposium September 15-17, 2017**

Current Practice	Best Practice	Resulting Gaps	Outcome Indicated	Learning Objective
Many medical providers do not apply current best practices in managing anxiety states. <sup>1-10</sup>	Evidence-based, personalized management of anxiety states, including the use of pharmacologic and nonpharmacologic therapies, results in improved patient outcomes and safety. <sup>11-29</sup>	Knowledge about and application of evidence-based management of anxiety states.	Knowledge Competence	Describe the evidence-based management of anxiety states.
Many medical providers do not apply current best practices in the use of benzodiazepines, including indications and contraindications. <sup>30-40</sup>	Evidence-based, personalized use of benzodiazepines results in improved patient outcomes and safety. <sup>29-34,41-43</sup>	Knowledge about evidence-based benzodiazepine neurophysiology, indications, risks <sup>32,44-60</sup> , and contraindications.	Knowledge Competence	Describe the evidence-based safe use of benzodiazepines in various clinical settings.
Many medical providers do not apply current best practices in managing adverse reactions to benzodiazepine use. <sup>30,36-41,44,60</sup>	Evidence-based, personalized approaches to identifying and then managing benzodiazepine adverse reactions results in improved patient outcomes and safety. <sup>32,44,49,62-70</sup>	Knowledge about benzodiazepine risks <sup>30-33,42,44-51,53-61,71-81</sup> for and evidence-based management <sup>82</sup> of benzodiazepine adverse reactions.	Knowledge Competence	Describe the evidence-based management of adverse reactions to benzodiazepine use.
Health systems lack effective application of approaches for the safe use of benzodiazepines by medical providers, payors, regulators, and the general public. <sup>83-87</sup>	Evidence-based use of health system approaches to safe and effective management of anxiety states, including the use of benzodiazepines and other medications, results in improved patient outcomes and public safety. <sup>43,50,84-</sup>	Application of evidence-based approaches to managing anxiety states, including the appropriate use of medications.	Knowledge Competence Performance	Describe evidence-based approaches that can be used by health systems to improve clinical management of anxiety states, including the safe and effective use of medications.

Steven Wright, MD  
11/18/16

Family Medicine  
Addiction Medicine  
Medical Pain Management

**Gap Analysis: Benzodiazepines**  
**The International Benzodiazepine Symposium September 15-17, 2017**

Program Medical Director  
The International Benzodiazepine Symposium  
[sleighwright@gmail.com](mailto:sleighwright@gmail.com)

**References**

- <sup>1</sup> Ballenger JC, Davidson JR, Lecrubier Y, et al. Consensus statement update on posttraumatic stress disorder from the international consensus group on depression and anxiety. *J Clin Psychiatry*. 2004;65 Suppl 1:55-62. [Abstract](#)
- <sup>2</sup> Culpepper L. Generalized anxiety disorder in primary care: emerging issues in management and treatment. *J Clin Psychiatry*. 2002;63 Suppl 8:35-42. [Abstract](#)
- <sup>3</sup> Kroenke K, Spitzer RL, Williams JB, et al. Anxiety disorders in primary care: prevalence, impairment, comorbidity, and detection. *Ann Intern Med*. 2007;146(5):317-25. [Abstract](#)
- <sup>4</sup> Menninger WW. Challenges to providing integrated treatment of anxiety disorders. *Bull Menninger Clin*. 1995;59(2 Suppl A):A86-93; quiz A94-7. [Abstract](#)
- <sup>5</sup> Nutt DJ, Kessler RC, Alonso J, et al. Consensus statement on the benefit to the community of ESEMeD (European Study of the Epidemiology of Mental Disorders) survey data on depression and anxiety. *J Clin Psychiatry*. 2007;68 Suppl 2:42-8. [Abstract](#)
- <sup>6</sup> Roy-Byrne PP, Wagner A. Primary care perspectives on generalized anxiety disorder. *J Clin Psychiatry*. 2004;65 Suppl 13:20-6. [Abstract](#)
- <sup>7</sup> Shear MK, Schulberg HC. Anxiety disorders in primary care. *Bull Menninger Clin*. 1995;59(2 Suppl A):A73-85. [Abstract](#)
- <sup>8</sup> Wittchen HU, Kessler RC, Beesdo K, et al. Generalized anxiety and depression in primary care: prevalence, recognition, and management. *J Clin Psychiatry*. 2002;63 Suppl 8:24-34. [Abstract](#)
- <sup>9</sup> Weisberg RB, Dyck I, Culpepper L, Keller MB. Psychiatric treatment in primary care patients with anxiety disorders: a comparison of care received from primary care providers and psychiatrists. *Am J Psychiatry*. 2007;164(2):276-82. [Article](#)

## **Gap Analysis: Benzodiazepines**

### **The International Benzodiazepine Symposium September 15-17, 2017**

<sup>10</sup> Stein MB, Sherbourne CD, Craske MG, et al. Quality of care for primary care patients with anxiety disorders. *Am J Psychiatry*. 2004;161(12):2230-7. [Abstract](#)

<sup>11</sup> Craven MA, Bland R. Better practices in collaborative mental health care: an analysis of the evidence base. *Can J Psychiatry*. 2006;51(6 Suppl 1):7S-72S. [Abstract](#)

<sup>12</sup> Australian and New Zealand clinical practice guidelines for the treatment of panic disorder and agoraphobia. Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guidelines Team for Panic Disorder and Agoraphobia. *Aust N Z J Psychiatry*. 2003;37(6):641-56. [Abstract](#)

<sup>13</sup> Ballenger JC, Davidson JR, Lecrubier Y, et al. Consensus statement on generalized anxiety disorder from the International Consensus Group on Depression and Anxiety. *J Clin Psychiatry*. 2001;62 Suppl 11:53-8. [Abstract](#)

<sup>14</sup> Heuzenroeder L, Donnelly M, Haby MM, et al. Cost-effectiveness of psychological and pharmacological interventions for generalized anxiety disorder and panic disorder. *Aust N Z J Psychiatry*. 2004;38(8):602-12. [Abstract](#)

<sup>15</sup> Ravindran AV, da Silva TL. Complementary and alternative therapies as add-on to pharmacotherapy for mood and anxiety disorders: a systematic review. *J Affect Disord*. 2013;150(3):707-19. [Abstract](#)

<sup>16</sup> Qureshi NA, Al-Bedah AM. Mood disorders and complementary and alternative medicine: a literature review. *Neuropsychiatr Dis Treat*. 2013;9:639-58. [Article](#)

<sup>17</sup> Bisson JI, Roberts NP, Andrew M, et al. Psychological therapies for chronic post-traumatic stress disorder (PTSD) in adults. *Cochrane Database Syst Rev*. 2013;(12):CD003388. [Abstract](#)

<sup>18</sup> Pompoli A, Furukawa TA, Imai H, et al. Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis. *Cochrane Database Syst Rev*. 2016;4:CD011004. [Abstract](#)

<sup>19</sup> Thorp SR, Ayers CR, Nuevo R, et al. Meta-analysis comparing different behavioral treatments for late-life anxiety. *Am J Geriatr Psychiatry*. 2009;17(2):105-15. [Article](#)

## **Gap Analysis: Benzodiazepines**

### **The International Benzodiazepine Symposium September 15-17, 2017**

- <sup>20</sup> Hofmann SG, Wu JQ, Boettcher H. Effect of cognitive-behavioral therapy for anxiety disorders on quality of life: a meta-analysis. *J Consult Clin Psychol*. 2014;82(3):375-91. [Article](#)
- <sup>21</sup> Hofmann SG, Sawyer AT, Witt AA, Oh D. The effect of mindfulness-based therapy on anxiety and depression: A meta-analytic review. *J Consult Clin Psychol*. 2010;78(2):169-83. [Article](#)
- <sup>22</sup> Pittler MH, Ernst E. Kava extract for treating anxiety. *Cochrane Database Syst Rev*. 2003;(1):CD003383. [Abstract](#)
- <sup>23</sup> Carter NJ, McCormack PL. Duloxetine: a review of its use in the treatment of generalized anxiety disorder. *CNS Drugs*. 2009;23(6):523-41. [Abstract](#)
- <sup>24</sup> Hendriks GJ, Keijsers GP, Kampman M, et al. A randomized controlled study of paroxetine and cognitive-behavioral therapy for late-life panic disorder. *Acta Psychiatr Scand*. 2010;122(1):11-9. [Abstract](#)
- <sup>25</sup> Mogg K, Baldwin DS, Brodrick P, Bradley BP. Effect of short-term SSRI treatment on cognitive bias in generalized anxiety disorder. *Psychopharmacology (Berl)*. 2004;176(3-4):466-70. [Abstract](#)
- <sup>26</sup> Imai H, Tajika A, Chen P, et al. Psychological therapies versus pharmacological interventions for panic disorder with or without agoraphobia in adults. *Cochrane Database Syst Rev*. 2016;10:CD011170. [Abstract](#)
- <sup>27</sup> van Apeldoorn FJ, Timmerman ME, Mersch PP, et al. A randomized trial of cognitive-behavioral therapy or selective serotonin reuptake inhibitor or both combined for panic disorder with or without agoraphobia: treatment results through 1-year follow-up. *J Clin Psychiatry*. 2010;71(5):574-86. [Abstract](#)
- <sup>28</sup> van Apeldoorn FJ, Stant AD, van Hout WJ, et al. Cost-effectiveness of CBT, SSRI, and CBT+ SSRI in the treatment for panic disorder. *Acta Psychiatr Scand*. 2014;129(4):286-95. [Abstract](#)
- <sup>29</sup> National Institute for Health and Care Excellence. Generalized anxiety disorder and panic disorder (with or without agoraphobia) in adults: management in primary, secondary and community care. January 2011. [Document](#) Accessed 11/16/16
- <sup>30</sup> Lader M. Benzodiazepines revisited - will we ever learn? *Addiction*. 2011;106(12):2086-109. [Abstract](#)

## **Gap Analysis: Benzodiazepines**

### **The International Benzodiazepine Symposium September 15-17, 2017**

- <sup>31</sup> Lader MH. Limitations on the use of benzodiazepines in anxiety and insomnia: are they justified? *Eur Neuropsychopharmacol*. 1999;9 Suppl 6:S399-405. [Abstract](#)
- <sup>32</sup> Lader M. Benzodiazepine harm: how can it be reduced? *Br J Clin Pharmacol*. 2014;77(2):295-301. [Article](#)
- <sup>33</sup> Lader M, Petursson H. Rational use of anxiolytic / sedative drugs. *Drugs*. 1983;25(5):514-28. [Abstract](#)
- <sup>34</sup> [American Geriatrics Society 2015 updated Beers Criteria for potentially inappropriate medication use in older adults](#). Accessed 11/17/16
- <sup>35</sup> [American Geriatrics Society: Beers Criteria Table. 2012](#). Accessed 11/18/16
- <sup>36</sup> Yang PJ, Lee YT, Tzeng SL, et al. Potentially inappropriate prescribing in disabled older patients with chronic diseases: a Screening Tool of Older Persons' potentially inappropriate Prescriptions versus Beers 2012 Criteria. *Med Princ Pract*. 2015;24(6):565-70. [Article](#)
- <sup>37</sup> Cannon KT, Choi MM, Zuniga MA. Potentially inappropriate medication use in elderly patients receiving home health care: a retrospective data analysis. *Am J Geriatr Pharmacother*. 2006;4(2):134-43. [Abstract](#)
- <sup>38</sup> Paulozzi LJ, Stickler GK, Kreiner PW, et al. Controlled substance prescribing patterns - Prescription Behavior Surveillance System, Eight States, 2013. *MMWR Surveill Summ*. 2015;64(9):1-14. [Abstract](#)
- <sup>39</sup> Buck MD, Atreja A, Brunker CP, et al. Potentially inappropriate medication prescribing in outpatient practices: prevalence and patient characteristics based on electronic health records. *Am J Geriatr Pharmacother*. 2009;7(2):84-92. [Abstract](#)
- <sup>40</sup> Gallagher P, Barry P, O'Mahony D. Inappropriate prescribing in the elderly. *J Clin Pharm Ther*. 2007;32(2):113-21. [Abstract](#)
- <sup>41</sup> Barry PJ, O'Keefe N, O'Connor KA, O'Mahony D. Inappropriate prescribing in the elderly: a comparison of the Beers criteria and the improved prescribing in the elderly tool (IPET) in acutely ill elderly hospitalized patients. *J Clin Pharm Ther*. 2006;31(6):617-26. [Abstract](#)
- <sup>42</sup> Goffinet S. Mechanism of action, indications and abuse of benzodiazepine anxiolytic drugs. *Ann Med Psychol (Paris)*. 1993;151(1):47-63. [Abstract](#)
- <sup>43</sup> Kashyap M, D'Cruz S, Sachdev A, Tiwari P. Evidence-based information leads to reduction in inappropriate drug prescribing: Results from Indian older inpatients. *Int J Risk Saf Med*. 2015;27(4):209-17. [Abstract](#)

## **Gap Analysis: Benzodiazepines**

### **The International Benzodiazepine Symposium September 15-17, 2017**

- <sup>44</sup> Uhlenhuth EH, Balter MB, Ban TA, Yang K. International study of expert judgment on therapeutic use of benzodiazepines and other psychotherapeutic medications: IV. Therapeutic dose dependence and abuse liability of benzodiazepines in the long-term treatment of anxiety disorders. *J Clin Psychopharmacol*. 1999;19(6 Suppl 2):23S-29S. [Abstract](#)
- <sup>45</sup> Weisberg DF, Gordon KS, Barry DT, et al. Long-term prescription of opioids and/or benzodiazepines and mortality among HIV-infected and uninfected patients. *J Acquir Immune Defic Syndr*. 2015;69(2):223-33. [Article](#)
- <sup>46</sup> Jones JD, Mogali S, Comer SD. Polydrug abuse: a review of opioid and benzodiazepine combination use. *Drug Alcohol Depend*. 2012;125(1-2):8-18. [Article](#)
- <sup>47</sup> Jones, KA, Nielsen S, Bruno R, et al. Benzodiazepines - Their role in aggression and why GPs should prescribe with caution. *Aust Fam Physician*. 2011;40(11):862-5. [Article](#)
- <sup>48</sup> Lee SC, Klein-Schwartz W, Doyon S, Welsh C. Comparison of toxicity associated with nonmedical use of benzodiazepines with buprenorphine or methadone. *Drug Alcohol Depend*. 2014;138:118-23. [Abstract](#)
- <sup>49</sup> Lintzeris N, Nielsen S. Benzodiazepines, methadone and buprenorphine: interactions and clinical management. *Am J Addict*. 2010;19(1):59-72. [Abstract](#)
- <sup>50</sup> Siegler A, Tuazon E, Bradley O'Brien D, Paone D. Unintentional opioid overdose deaths in New York City, 2005-2010: place-based approach to reduce risk. *Int J Drug Policy*. 2014;25(3):569-74. [Abstract](#)
- <sup>51</sup> Shah NA, Abate MA, Smith MJ, et al. Characteristics of alprazolam-related deaths compiled by a centralized state medical examiner. *Am J Addict*. 2012;21 Suppl 1:S27-34. [Abstract](#)
- <sup>52</sup> Brazens JG, Kornør H. Benzodiazepine prescription for patients in opioid maintenance treatment in Norway. *Drug Alcohol Depend*. 2007;90(2-3):203-9. [Abstract](#)
- <sup>53</sup> Brands B, Blake J, Marsh DC, et al. The impact of benzodiazepine use on methadone maintenance treatment outcomes. *J Addict Dis*. 2008;27(3):37-48. [Abstract](#)

## **Gap Analysis: Benzodiazepines**

### **The International Benzodiazepine Symposium September 15-17, 2017**

- <sup>54</sup> Park TW, Saitz R, Ganoczy D, et al. Benzodiazepine prescribing patterns and deaths from drug overdose among US veterans receiving opioid analgesics: case-cohort study. *BMJ*. 2015;350:h2698. [Article](#)
- <sup>55</sup> Rich BA, Webster LR. A review of forensic implications of opioid prescribing with examples from malpractice cases involving opioid-related overdose. *Pain Med*. 2011;12 Suppl 2:S59-65. [Article](#)
- <sup>56</sup> Webster LR, Cochella S, Dasgupta N, et al. An analysis of the root causes for opioid-related overdose deaths in the United States. *Pain Med*. 2011;12 Suppl 2:S26-35. [Article](#)
- <sup>57</sup> Jann M, Kennedy WK, Lopez G. Benzodiazepines: a major component in unintentional prescription drug overdoses with opioid analgesics. *J Pharm Pract*. 2014;27(1):5-16. [Abstract](#)
- <sup>58</sup> Bachhuber MA, Hennessy S, Cunningham CO, Starrels JL. Increasing benzodiazepine prescriptions and overdose mortality in the United States, 1996–2013. *Am J Public Health*. 2016;106(4):686-8. [Article](#)
- <sup>59</sup> CDC. Vital signs: ODs of prescription opioid pain relievers, other drugs among US women 1999-2010. *MMWR Morb Mortal Wkly Rep*. 2013;62(26):537-42. [Article](#)
- <sup>60</sup> Green TC, Grau LE, Carver HW, et al. Epidemiologic trends and geographic patterns of fatal opioid intoxications in Connecticut, USA: 1997-2007. *Drug Alcohol Depend*. 2011;115(3):221-8. [Article](#)
- <sup>61</sup> Miller NS, Gold MS. Benzodiazepines: a major problem. Introduction. *J Subst Abuse Treat*. 1991;8(1-2):3-7. [Abstract](#)
- <sup>62</sup> Couvée JE, Timmermans MA, Zitman FG. The long-term outcome of a benzodiazepine discontinuation program in depressed outpatients. Dutch Chronic Benzodiazepine Working Group. *J Affect Disord*. 2002;70(2):133-41. [Abstract](#)
- <sup>63</sup> Gorgels WJ, Oude Voshaar RC, Mol AJ, et al. Predictors of discontinuation of benzodiazepine prescription after sending a letter to long-term benzodiazepine users in family practice. *Fam Pract*. 2006;23(1):65-72. [Article](#)
- <sup>64</sup> Kan CC, Mickers FC, Barnhoorn D. Short- and long-term results of a systematic benzodiazepine discontinuation programme for psychiatric patients. *Tijdschr Psychiatr*. 2006;48(9):683-93. [Abstract](#)

## **Gap Analysis: Benzodiazepines**

### **The International Benzodiazepine Symposium September 15-17, 2017**

- <sup>65</sup> Lader M, Kyriacou A. Withdrawing benzodiazepines in patients with anxiety disorders. *Curr Psychiatry Rep.* 2016;18(1):8. [Abstract](#)
- <sup>66</sup> Lader M, Tylee A, Donoghue J. Withdrawing benzodiazepines in primary care. *CNS Drugs.* 2009;23(1):19-34. [Abstract](#)
- <sup>67</sup> Lemoine P, Touchon J, Billardon M. Comparison of 6 different methods for lorazepam withdrawal. A controlled study, hydroxyzine versus placebo. *Encephale.* 1997;23(4):290-9. [Abstract](#)
- <sup>68</sup> Parr JM, Kavanagh DJ, Cahill L, et al. Effectiveness of current treatment approaches for benzodiazepine discontinuation: a meta-analysis. *Addiction.* 2009;104(1):13-24. [Abstract](#)
- <sup>69</sup> Pollmann AS, Murphy AL, Bergman JC, Gardner DM. Deprescribing benzodiazepines and Z-drugs in community-dwelling adults: a scoping review. *BMC Pharmacol Toxicol.* 2015;16:19. [Article](#)
- <sup>70</sup> Voshaar RC, Couvée JE, van Balkom AJ, et al. Strategies for discontinuing long-term benzodiazepine use: meta-analysis. *Br J Psychiatry.* 2006;189:213-20. [Abstract](#)
- <sup>71</sup> Uzun S, Kozumplik O, Jakovljević M, Sedić B. Side effects of treatment with benzodiazepines. *Psychiatr Danub.* 2010;22(1):90-3. [Article](#)
- <sup>72</sup> Mason M, Cates CJ, Smith I. Effects of opioid, hypnotic and sedating medications on sleep-disordered breathing in adults with obstructive sleep apnea. *Cochrane Database Syst Rev.* 2015;7:CD011090. [Abstract](#)
- <sup>73</sup> Billioti de Gage S, Boride Y, Ducret T, et al. Benzodiazepine use and risk of Alzheimer's disease: case-control study. *BMJ.* 2014;349:g5205. [Article](#)
- <sup>74</sup> Pariente A, de Gage SB, Moore N, Bégaud B. The benzodiazepine-dementia disorders link: current state of knowledge. *CNS Drugs.* 2016;30(1):1-7. [Abstract](#)
- <sup>75</sup> Hsiao F-Y, Peng L-N, Lin M-G, et al. Dose-responsive effect of psychotropic drug use and subsequent dementia: a nationwide propensity score matched case-control study in Taiwan. *J Am Med Dir Assoc.* 2014;15(7):509-13. [Abstract](#)
- <sup>76</sup> Mura R, Proust-Lima C, Akbaraly T, et al. Chronic use of benzodiazepines and latent cognitive decline in the elderly: results from the Three-City Study. *Eur Neuropsychopharm.* 2013;23(3):212-23. [Abstract](#)
- <sup>77</sup> Rapeli P, Fabritius C, Kalska H, Alho H. Memory function in opioid-dependent patients treated with methadone or buprenorphine along with benzodiazepine: longitudinal change in comparison to healthy individuals. *Subst Abuse Treat Prev Policy.* 2009;4:6 [Article](#)



**Gap Analysis: Benzodiazepines**  
**The International Benzodiazepine Symposium September 15-17, 2017**

- <sup>78</sup> Person EP, Gray SL, Hanlon JT. Medication use and functional status decline in older adults: a narrative review. *Am J Geriatr Pharmacother.* 2011;9(6):378-91. [Article](#)
- <sup>79</sup> Gillet C, Polard E, Mauduit N, Allain H. Acting out and psychoactive substances: alcohol, drugs, illicit substances. *Encephale.* 2001;27(4):351-9. [Abstract](#)
- <sup>80</sup> Dassanayake T, Michie P, Carter G, Jones A. Effects of benzodiazepines, antidepressants and opioids on driving: a systematic review and meta-analysis of epidemiological and experimental evidence. *Drug Saf.* 2011;34(2):125-56. [Abstract](#)
- <sup>81</sup> Walton GR, Hayashi K, Bach P, et al. The impact of benzodiazepine use on mortality among polysubstance users in Vancouver, Canada. *Public Health Rep.* 2016;131(3):491-9. [Abstract](#)
- <sup>82</sup> Walter A, Chew-Graham C, Harrison S. Negotiating refusal in primary care consultations: a qualitative study. *Fam Pract.* 2012;29(4):488-96. [Abstract](#)
- <sup>83</sup> Bachhuber MA, Maughan BC, Mitra N, et al. Prescription monitoring programs and emergency department visits involving benzodiazepine misuse: Early evidence from 11 United States metropolitan areas. *Int J Drug Policy.* 2016;28:120-3. [Abstract](#)
- <sup>84</sup> Murthy L, Shepperd S, Clarke MJ, et al. Interventions to improve the use of systematic reviews in decision-making by health system managers, policy makers and clinicians. *Cochrane Database Syst Rev.* 2012;(9):CD009401. [Abstract](#)
- <sup>85</sup> Ryan R, Santesso N, Lowe D, et al. Interventions to improve safe and effective medicines use by consumers: an overview of systematic reviews. *Cochrane Database Syst Rev.* 2014;(4):CD007768. [Abstract](#)
- <sup>86</sup> Arditi C, Rège-Walther M, Wyatt JC, et al. Computer-generated reminders delivered on paper to healthcare professionals; effects on professional practice and health care outcomes. *Cochrane Database Syst Rev.* 2012;12:CD001175. [Abstract](#)
- <sup>87</sup> Pedrana L, Pamponet M, Walker R, et al. Scoping review: national monitoring frameworks for social determinants of health and health equity. *Glob Health Action.* 2016;9:28831. [Article](#)

## **Gap Analysis: Benzodiazepines**

### **The International Benzodiazepine Symposium September 15-17, 2017**

- <sup>88</sup> Tamblyn R, Huang A, Perreault R, et al. The medical office of the 21st century (MOXXI): effectiveness of computerized decision-making support in reducing inappropriate prescribing in primary care. *CMAJ*. 2003;169(6):549-56. [Abstract](#)
- <sup>89</sup> Cooper JA, Cadogan CA, Patterson SM, et al. Interventions to improve the appropriate use of polypharmacy in older people: a Cochrane systematic review. *BMJ Open*. 2015;5(12):e009235. [Article](#)
- <sup>90</sup> Nkansah N, Mostovetsky O, Yu C, et al. Effect of outpatient pharmacists' non-dispensing roles on patient outcomes and prescribing patterns. *Cochrane Database Syst Rev*. 2010;(7):CD000336. [Abstract](#)
- <sup>91</sup> Pande S, Hiller JE, Nkansah N, Bero L. The effect of pharmacist-provided non-dispensing services on patient outcomes, health service utilisation and costs in low- and middle-income countries. *Cochrane Database Syst Rev*. 2013;(2):CD010398. [Abstract](#)
- <sup>92</sup> Castelino RL, Bajorek BV, Chen TF. Targeting suboptimal prescribing in the elderly: a review of the impact of pharmacy services. *Ann Pharmacother*. 2009;43(6):1096-106. [Abstract](#)
- <sup>93</sup> Allen D, Gillen E, Rixson L. The effectiveness of integrated care pathways for adults and children in health care settings: a systematic review. *JBI Libr Syst Rev*. 2009;7(3):80-129. [Abstract](#)
- <sup>94</sup> Flodgren G, Eccles MP, Shepperd S, et al. An overview of reviews evaluating the effectiveness of financial incentives in changing healthcare professional behaviors and patient outcomes. *Cochrane Database Syst Rev*. 2011;(7):CD009255. [Article](#)
- <sup>95</sup> Scott A, Sivey P, Ait Ouakrim D, et al. The effect of financial incentives on the quality of health care provided by primary care physicians. *Cochrane Database Syst Rev*. 2011;(9):CD008451. [Abstract](#)
- <sup>96</sup> [National Institute for Health and Care Excellence \(NICE\) Guideline: Controlled drugs: safe use and management. 2016.](#) Accessed 11/18/16
- <sup>97</sup> [National Institute for Health and Care Excellence \(NICE\) Guideline: Self-harm longer term management. 2011.](#) Accessed 11/18/16
- <sup>98</sup> [National Institute for Health and Care Excellence \(NICE\) Guideline: Drug misuse psychosocial interventions. 2007.](#) Accessed 11/18/16

**Gap Analysis: Benzodiazepines**  
**The International Benzodiazepine Symposium September 15-17, 2017**

Steven Wright, MD  
11/18/16

Family Medicine  
Addiction Medicine  
Medical Pain Management

Program Medical Director  
The International Benzodiazepine Symposium  
[sleighwright@gmail.com](mailto:sleighwright@gmail.com)